{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:13:00Z","timestamp":1781273580700,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"DOI":"10.7759\/cureus.90657","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:40:53Z","timestamp":1755776453000},"source":"Crossref","is-referenced-by-count":4,"title":["Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report"],"prefix":"10.7759","author":[{"given":"Nicholas","family":"Lorenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Abouafech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amia","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins L","year":"2025","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao X","year":"2021","unstructured":"Zhao X, Wang M, Wen Z, et al.. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021, 12:721135. 10.3389\/fendo.2021.721135","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian D","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et al.. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025, 122:344-67. 10.1016\/j.ajcnut.2025.04.023","journal-title":"Am J Clin Nutr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09825-1","article-title":"Beyond glycemia: comparing tirzepatide to GLP-1 analogues","volume":"24","author":"Andraos J","year":"2023","unstructured":"Andraos J, Muhar H, Smith SR. Beyond glycemia: comparing tirzepatide to GLP-1 analogues. Rev Endocr Metab Disord. 2023, 24:1089-101. 10.1007\/s11154-023-09825-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref5","unstructured":"Zepbound (tirzepatide). Accessed. August 17, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217806s000lbl.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra R","year":"2023","unstructured":"Mishra R, Raj R, Elshimy G, et al.. Adverse events related to tirzepatide. J Endocr Soc. 2023, 7:bvad016. 10.1210\/jendso\/bvad016","journal-title":"J Endocr Soc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe CS","year":"2011","unstructured":"Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011, 2011:279530. 10.1155\/2011\/279530","journal-title":"Exp Diabetes Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88350","article-title":"Semaglutide-induced small bowel pseudo-obstruction and ileitis in a patient with type 2 diabetes: a case report","volume":"17","author":"Javed F","year":"2025","unstructured":"Javed F, Shaat IA, Oyibo SO. Semaglutide-induced small bowel pseudo-obstruction and ileitis in a patient with type 2 diabetes: a case report. Cureus. 2025, 17:e88350. 10.7759\/cureus.88350","journal-title":"Cureus"},{"key":"ref9","article-title":"Small bowel obstruction","author":"Schick MA","year":"2025","unstructured":"Schick MA, Kashyap S, Collier SA, Meseeha M. Small bowel obstruction. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref10","article-title":"Small bowel obstruction","author":"Kulaylat MN","year":"2001","unstructured":"Kulaylat MN, Doerr RJ. Small bowel obstruction. Surgical Treatment: Evidence-Based and Problem-Oriented. Holzheimer RG, Mannick JA (ed): 2001."},{"key":"ref11","article-title":"Small intestinal bacterial overgrowth: a comprehensive review","volume":"3","author":"Dukowicz AC","year":"2007","unstructured":"Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007, 3:112-22.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.19080\/ARGH.2023.19.556023","article-title":"Adynamic ileus in hospitalized adults: current concepts and practices","volume":"19","author":"Velasquez GD","year":"2023","unstructured":"Velasquez GD, Rodriguez ME, Guilarte JA, et al.. Adynamic ileus in hospitalized adults: current concepts and practices. Adv Res Gastroentero Hepatol. 2023, 19:556023. 10.19080\/ARGH.2023.19.556023","journal-title":"Adv Res Gastroentero Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al.. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024, 110:1-15. 10.1210\/clinem\/dgae719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.7.2212","article-title":"Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects","volume":"54","author":"Meier JJ","year":"2005","unstructured":"Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005, 54:2212-8. 10.2337\/diabetes.54.7.2212","journal-title":"Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399219-nonmechanical-small-bowel-obstruction-in-a-patient-on-zepbound-without-a-surgical-history-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:40:54Z","timestamp":1755776454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399219-nonmechanical-small-bowel-obstruction-in-a-patient-on-zepbound-without-a-surgical-history-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.90657","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}